ArticleInternational journal of pharmaceutics: X2026
Allicin-based biomimetic nanoparticles of the erythrocyte membrane for the delivery of lumefantrine to enhance its antimalarial effect.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the emergence of drug resistance and the lack of effective vaccines, malaria continues to seriously harm the physical and mental health of a multitude of individuals, warranting the need to explore new antimalarial strategies. In this study, we developed allicin-based biomimetic nanoparticles of the erythrocyte membrane (PECm-Allicin@LM) through a sonication method for the delivery of lumefantrine (LM), a hydrophobic antimalarial drug. PECm-Allicin@LM showed regular spherical morphology with a mean diameter of 120 nm and retained most of the major proteins on the erythrocyte membrane. PECm-Allicin@LM was stable and sustained the release of LM. Flow cytometry analysis showed that PECm-Allicin@LM could deliver LM to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.